期刊文献+

MICA的基因多态性及其临床意义 被引量:1

MICA polymorphism and clinical implication
下载PDF
导出
摘要 经典的主要组织相容性复合体(MHC)在排斥反应的发生、发展方面具有重要作用,但越来越多的研究表明某些非经典MHC基因在此过程中,乃至在其他疾病的免疫机制方面同样意义显著。主要组织相容性复合体Ⅰ类分子链相关基因A(major histocompatibility complex class I related chain A,MICA)即属于非经典MHC-I类基因。大量研究表明,作为最具多态性的非经典MHC-I类基因,其表达产物可借助NKG2D与自然杀伤细胞、某些特定T细胞亚群等多种免疫细胞相互作用,从而在病毒感染的免疫监视、自身免疫性疾病与器官移植排斥反应的发生发展方面均具有重要意义。 The classical major histocompatibility complex (MHC) plays major roles in the initiation and progression of rejection, more and more researches indicate some non-classical MHC also participate in this process and immune mechanism of other diseases significantly. The MHC-I related chain A (MICA) belongs to the non-classical MHC- I family. Numerous studies demonstrate that the expression products of MICA interact with NK cells, some specialized class of T cells and other immunocytes via NKG2D as the non-classical MHC molecule with the most polymorphisms, and then associate with not only the immunosurveillance of viral infection, but also the development of autoimmune disease and rejection of organ transplantation extremely.
作者 吴迪 孙启全
出处 《肾脏病与透析肾移植杂志》 CAS CSCD 北大核心 2011年第4期378-383,共6页 Chinese Journal of Nephrology,Dialysis & Transplantation
基金 国家自然科学基金(81070593)
关键词 MICA 多态性 病毒感染 自身免疫性疾病 器官移植 MICA polymorphism viral infection autoimmune disease organ transplantation
  • 相关文献

参考文献41

  • 1Bahram S, Bresnahan M, Geraghty DE, et al. A second lineage of mammalian major histocompatibility complex class I genes. Proc Natl Acad Sci U S A,1994,91 (14) :6259 -6263.
  • 2Leelayuwat C, Townend DC, Degli-Esposti MA, et al. AneWto polymorphic and multicopy MHC gene family related nonmammalian class I. Immunogenetics, 1994,40 (5) :339 - 351.
  • 3Horton R, Wilming L, Rand V, et al. Gene map of the extended human MHC. Nat Rev Genet,2004,5 (12) :889 -899.
  • 4Shiina T, Tamiya G, Oka A, et al. Molecular dynamics of MHC genesis unraveled by sequence analysis of the 1,796,938-bp HLA class I region. Proc Natl Acad Sci USA, 1999, 96 (23):13282 - 13287.
  • 5Hegel WA. Will MICA Glitter for Recipients of Kidney Transplants? N Engl J Med ,2007,357 ( 13 ) : 1337 - 1339.
  • 6Stephens HA. MICA and MICB genes: can the enigma of their polymorphism be resolved? Trends in Immunol, 2001,22 ( 7 ) : 378 - 385.
  • 7Groh V, Rhinehart R, Randolph-Habecker J, et al. Costimulation of CD8alphabeta T ceils by NKG2D via engagement by MIC induced on virus-infected cells. Nat Immunol,2001,2 ( 3 ) :255 - 260.
  • 8Schreiner B, Voss J, Wischhusen J, et al. Expression of toll-like receptors by human muscle ceils in vitro and in vivo:TLR3 is highly expressed in inflammatory and HIV myopathies, mediates IL-8 release and up-regulation of NKG2D-ligands. FASEB J, 2006,20 (1) : 118 - 120.
  • 9Tang KF, Ren H, Cao J, et al. Decreased Dicer expression elicits DNA damage and up-regulation of MICA and MICB. J Cell Biol, 2008,182(2) :233 -239.
  • 10Hankey KG, Drachenberg CB, Papadimitriou JC, et al. MIC expression in renal and pancreatic allografts. Transplantation, 2002,73 ( 2 ) : 304 - 306.

二级参考文献12

  • 1孙启全 ,刘志红 ,陈劲松 ,陈惠萍 ,季大玺 ,尹广 ,季曙明 ,周虹 ,唐政 ,黎磊石 ,LI Leishi .移植肾组织C4d阳性急性排斥21例临床观察[J].肾脏病与透析肾移植杂志,2005,14(1):12-17. 被引量:11
  • 2Ferry BL, Welsh KI, Dunn M J, et al. Anti-cell surface endothelial antibodies in sera from cardiac and kidney transplant recipients: association with chronic rejection. Transpl Immunol, 1997, 5:17 -24.
  • 3Sun Q,Liu Z,Yin G, Chen J, et al. Circulating anti-endothelial cell antibodies are associated with poor outcome in renal allograft recipients with acute rejection. Clin J Am Soc Nephrol, 2008,3 (5) :1479 - 1456.
  • 4Solez K, Colvin RB, Racusen LC, et al. Banff' 05 meeting report: differential diagnosis of chronic allograft injury and elimination of chronic aUngraft nephropathy (CAN ). Am J Transplant, 2007,7 (3) :518 -526.
  • 5Sumitran-Holgersson S, Wilczek HE, Holgersson J, et al. Identification of the nonclassical HLA molecules, mica, as targets for humoral immunity associated'with irreversible rejection of kidney allografts. Transplantation, 2002,74:268 - 277.
  • 6Bahram S, Bresnahan M, Geraghty DE, et al. A second lineage of mammalian major histocompatibility complex class I genes. Proc Natl Acad Sci U S A,1994,91:6259 -6263.
  • 7Zou YZ, Stastny P, Susal C, et al. Antibodies against MICA Antigens and Kidney-Transplant Rejection. N Engl J Med, 2007,357:1293 - 1300.
  • 8Zou Y, Mirbaha F, Lazaro A, et al. MICA is a target for complement-dependent cytotoxicity with mouse monoclonal antibodies and human alloantibodies. Hum Immunol, 2002,63:30 - 39.
  • 9Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant, 2008,8 ( 4 ) :753 - 760.
  • 10Wen J, Li L, Chen J, et al. Tripterygium Wilfordii Hook F Increase the Blood Concentration of Tacrolimus. Transplant proc, 2008,40, 3679 - 3682.

共引文献1

同被引文献38

  • 1吕铁明,谭建明.转化生长因子β1基因型与移植肾慢性排斥反应的关系[J].中国医药生物技术,2007,2(1):28-31. 被引量:2
  • 2李川江,于立新,徐健,付绍杰,邓文锋,杜传福,王亦斌.转化生长因子β1基因多态性与慢性移植肾肾病的关系[J].南方医科大学学报,2007,27(4):535-537. 被引量:3
  • 3周惠忠,黎磊石.肾移植排异反应的机理与诊断.国际泌尿系统杂志,1987,2:15-17.
  • 4Fischereder M, Luckow B, Hocher B, et al. CC chemokine receptor 5 and renal transplant survival. Lancet, 2001, 357: 1758-1761.
  • 5Ro H, Hwang YH, Kim H, et al. Association of polymorphisms of interleukin-8, CXCR1, CXCR2, and selectin with allograft outcomes in kidney transplantation. Transplantation, 2011, 91: 57-64.
  • 6Rosso FC, De Sandes TV, Sampaio EL, et al. Clinical impact of polymorphisms of transport proteins and enzymes involved in the metabolism of immunosuppressive drugs. Transplant Proc, 2009, 41: 1441-1455.
  • 7Grenda R, Prokurat S, Ciechanowicz A, et al. Evaluation of the genetic background of standard-immtmosuppressant-related toxicity in a cohort of 200 paediatricrenal allograft recipients: a retrospective study. Ann Transplant, 2009, 14: 18-24.
  • 8Ozdemir V, Kalow W, Tang BK, et al. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics, 2000, 10: 373-388.
  • 9Hesselink DA, van Schaik RI-I, van der Heiden IP, et al. Genetic polymorphisms of the CYIA4, CYP3AS, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther, 2003, 74: 245-254.
  • 10Roy JN, Bamma A, Poirier C, et al. CYP3A4, CYP3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics inrenal transplant recipients. Pharmacogenet Genomics, 2006, 16: 659-665.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部